Clinical Trial Update: NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours [Phase 1, Phase 2]

View source ↗

Summary

NuCana plc announced termination of a Phase 1/2 trial evaluating NUC-3373 in combination with other agents for patients with advanced solid tumors. The update i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Esophageal Cancer
• Gastric Cancer
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma
• Triple-negative Breast Cancer
• Urothelial Carcinoma

Drugs mentioned

• NUC-3373

Snippet

Sponsor: NuCana plc | Conditions: Advanced Cancer, Advanced Solid Tumor | Phase 1, Phase 2 | Status: TERMINATED